We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| MorphoSys AG | NASDAQ:MOR | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 18.96 | 18.60 | 19.00 | 0 | 00:00:00 |
From Jan 2023 to Jan 2025
By Ben Glickman
MorphoSys said its study of a treatment for myelofibrosis, a rare form of blood cancer, reached its primary endpoint, clearing the way for a new drug application in mid-2024.
The German pharmaceutical company said Monday its Phase 3 trial of pelabresib in combination with ruxolitinib in myelofibrosis patients found a statistically significant and clinically meaningful improvement in the portion of patients with a 35% or greater reduction in spleen volume after 24 weeks.
There was also a meaningful reduction in myelofibrosis symptoms, a key secondary endpoint, according to the company.
MorphoSys now intends to submit a new drug application for pelabresib in combination with ruxolitinib to U.S. and European regulators in mid-2024.
The company's combination therapy received fast track designation from the Food and Drug Administration in treating myelofibrosis in 2018.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
November 20, 2023 17:04 ET (22:04 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year MorphoSys Chart |
1 Month MorphoSys Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
